ENTA Quote, Financials, Valuation and Earnings

NanoViricides, Inc. has a net margin of -123.64% compared to Enanta Pharmaceuticals, Inc.'s net margin of --. Enanta Pharmaceuticals, Inc.'s return on equity of -85.63% beat NanoViricides, Inc.'s return on equity of -92.29%.

Enanta Pharmaceuticals, Inc. has a consensus price target of $19.13, signalling upside risk potential of 35.74%. On the other hand NanoViricides, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 473.77%. Given that NanoViricides, Inc. has higher upside potential than Enanta Pharmaceuticals, Inc., analysts believe NanoViricides, Inc. is more attractive than Enanta Pharmaceuticals, Inc..

Enanta Pharmaceuticals, Inc. has a beta of 0.965, which suggesting that the stock is 3.527% less volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.

Enanta Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enanta Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.

Enanta Pharmaceuticals, Inc. quarterly revenues are $15.1M, which are larger than NanoViricides, Inc. quarterly revenues of --. Enanta Pharmaceuticals, Inc.'s net income of -$18.7M is lower than NanoViricides, Inc.'s net income of -$1.8M. Notably, Enanta Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enanta Pharmaceuticals, Inc. is 4.60x versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics, Inc. has a net margin of -123.64% compared to Enanta Pharmaceuticals, Inc.'s net margin of --. Enanta Pharmaceuticals, Inc.'s return on equity of -85.63% beat Oragenics, Inc.'s return on equity of -509.23%.

Enanta Pharmaceuticals, Inc. has a consensus price target of $19.13, signalling upside risk potential of 35.74%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 134.85%. Given that Oragenics, Inc. has higher upside potential than Enanta Pharmaceuticals, Inc., analysts believe Oragenics, Inc. is more attractive than Enanta Pharmaceuticals, Inc..

Enanta Pharmaceuticals, Inc. has a beta of 0.965, which suggesting that the stock is 3.527% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.

Enanta Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enanta Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.

Enanta Pharmaceuticals, Inc. quarterly revenues are $15.1M, which are larger than Oragenics, Inc. quarterly revenues of --. Enanta Pharmaceuticals, Inc.'s net income of -$18.7M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, Enanta Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enanta Pharmaceuticals, Inc. is 4.60x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -123.64% compared to Enanta Pharmaceuticals, Inc.'s net margin of --. Enanta Pharmaceuticals, Inc.'s return on equity of -85.63% beat Palatin Technologies's return on equity of --.

Enanta Pharmaceuticals, Inc. has a consensus price target of $19.13, signalling upside risk potential of 35.74%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Enanta Pharmaceuticals, Inc., analysts believe Palatin Technologies is more attractive than Enanta Pharmaceuticals, Inc..

Enanta Pharmaceuticals, Inc. has a beta of 0.965, which suggesting that the stock is 3.527% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Enanta Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enanta Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Enanta Pharmaceuticals, Inc. quarterly revenues are $15.1M, which are larger than Palatin Technologies quarterly revenues of --. Enanta Pharmaceuticals, Inc.'s net income of -$18.7M is higher than Palatin Technologies's net income of --. Notably, Enanta Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enanta Pharmaceuticals, Inc. is 4.60x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -123.64% compared to Enanta Pharmaceuticals, Inc.'s net margin of --. Enanta Pharmaceuticals, Inc.'s return on equity of -85.63% beat Theriva Biologics, Inc.'s return on equity of -171.04%.

Enanta Pharmaceuticals, Inc. has a consensus price target of $19.13, signalling upside risk potential of 35.74%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3398.25%. Given that Theriva Biologics, Inc. has higher upside potential than Enanta Pharmaceuticals, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Enanta Pharmaceuticals, Inc..

Enanta Pharmaceuticals, Inc. has a beta of 0.965, which suggesting that the stock is 3.527% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.

Enanta Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enanta Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Enanta Pharmaceuticals, Inc. quarterly revenues are $15.1M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Enanta Pharmaceuticals, Inc.'s net income of -$18.7M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Enanta Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enanta Pharmaceuticals, Inc. is 4.60x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.